[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Marc Blondon\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100603722","phase-3-short-term-low-dose-low-molecular-weight-heparin-to-prevent-postpartum-thrombosis-100603722",false,"NCT07140211","Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis","Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis: a Pragmatic, Multi-center, Open-label Randomized Controlled Study","SHINE","Inclusion Criteria: postpartum women after delivery AND ≥1 major risk factor \u002F ≥2 minor risk factors:\n\n* Major risk factors: Emergency cesarean section ; Pre-pregnancy BMI ≥35kg\u002Fm2 ; Known low-risk thrombophilia (heterozygous factor V Leiden; heterozygous G20210 prothrombin mutation) ; Pre-eclampsia ; Pre-term delivery ; Peripartum systemic infection ; Intra-uterine growth restriction ; Pregnancy loss\n* Minor risk factors: Age ≥35 years ; Pre-pregnancy BMI 30.0-34.9kg\u002Fm2 ; Current smoking ; Elective cesarean section ; Postpartum hemorrhage ; Antenatal immobility\n\nExclusion Criteria:\n\n* ≥2 doses of postpartum LMWH\n* Any indication for therapeutic anticoagulation\n* A high-risk of postpartum VTE\n* An increased bleeding risk\n* A contra-indication to heparin","FEMALE","18 Years",{"count":20,"type":21},9200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are:\n\n* compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery?\n* compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.",[27,28],"Venous Thromboembolism (VTE)","Postpartum","RECRUITING","2026-02-12",{"date":32,"type":33},"2026-02-17","ACTUAL",{"date":35,"type":33},"2025-10-15",{"date":37,"type":21},"2030-08",{"name":39,"class":40},"Marc Blondon","OTHER",""]